

Amarin Corp. Plc\Uk (AMRN)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000897448

Amarin Corp. Plc\Uk AMRN; healthcare	
Grade	E A B C D E weakest fifth of 371 graded peers percentile 84.3; sampling error 2.5 points; lower is stronger
Rank	313 of 371
Profitability	D percentile 69.9
Solvency	B/C percentile 41.3
Growth and financing	D/E percentile 77.5
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$670.8M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active; fortress balance sheet not computable: dilution
Inputs computable	8 of 14
Graded from	filings received through Mar 2, 2026 221 days before the rescans; latest periodic filing 10-Q received Jul 29, 2026
Last close	\$12.02 2026-10-08; market equity \$5.0B
Price used in grade	None




E, the bear

weakest fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: A/B from Mar 21, 2020, B from Feb 21, 2021, A/B from Mar 21, 2021, E from Mar 21, 2021

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 2, 2026

- Government Regulation - Pharmaceutical Pricing and Reimbursement for further details. In many countries outside the U.S., government-sponsored healthcare systems are the primary payors for drugs. With increasing budgetary constraints and differing views on or challenges in valuing medicines, governments and payors in many countries are applying a variety of measures to exert downward price pressure. These measures can include mandatory price controls, price referencing, therapeutic-reference pricing,

increases in mandates, incentives for generic substitution and biosimilar usage and government-mandated price cuts.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 69.9						
Gross profitability		18.0%	32.2%	65.8	372	2025-12-31
Return on invested capital		not computable	9.3%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Accruals ratio		(6.7%)	(6.6%)	55.6	811	2025-12-31
Gross margin stability, five years		14.3 pts	2.8 pts	88.4	243	2025-12-31
Solvency, sleeve percentile 41.3						
Twelve-month failure probability		0.04%	0.07%	25.5	248	2026-06-30
Altman Z double-prime		(2.07)	(0.31)	45.0	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000 interest expense must exceed \$100,000
Interest coverage		not computable	(4.51x)			
Current ratio		3.34x	2.96x	53.5	839	2025-12-31
Growth and financing, sleeve percentile 77.5						
Revenue growth, three-year compound		(16.7%)	10.0%	88.2	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		(8.9%)	2.1%	66.9	704	2025-12-31
Net share issuance, one year		not computable	2.5%			raw and split-adjusted prices do not align at 2013-02-20


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 594,886,000 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
308	SkinHealth Systems Inc. (SKIN)	83.0	E	
309	Karyopharm Therapeutics Inc. (KPTI)	83.2	E	dilution, distress, fortress balance sheet
310	Novavax Inc. (NVAX)	83.5	E	
311	Pyxis Oncology, Inc. (PYXS)	83.8	E	short runway, distress
312	Opko Health, Inc. (OPK)	84.1	E	fortress balance sheet
313	Amarin Corp. Plc\Uk (AMRN) <	84.3	E	fortress balance sheet
314	Kalaris Therapeutics, Inc. (KLRS)	84.6	E	dilution
315	Journey Medical Corp. (DERM)	84.9	E	
316	Amgen Inc. (AMGN)	85.1	E	
317	Organon & Co. (OGN)	85.4	E	
318	Sonoma Pharmaceuticals, Inc. (SNOA)	85.7	E	dilution, fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(15.3%)	8.0%	35
Distance from 52-week high	(40.8%)	(31.4%)	38
EBIT to enterprise value	(1.0%)	(1.5%)	51
Free cash flow yield	(0.4%)	(1.0%)	51
Book value to price	0.09	0.28	24
Sales to price	0.04	0.31	15
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(0.38)	(0.14)	35

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass

Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$143.6M
Operating cash flow, four quarters	\$15.6M
Months of runway	not finite
Days since last periodic filing	72 (10-Q received Jul 29, 2026)
Median daily dollar volume, 63 sessions	\$738,942

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$120.9M	2025-12-31	2026-03-02	10-K	0001193125-26-085818
2	assets	us-gaap:Assets	\$670.8M	2025-12-31	2026-03-02	10-K	0001193125-26-085818
3	operating income	us-gaap:OperatingIncomeLoss	-\$24.3M	2019-12-31	2022-03-01	10-K	0000950170-22-002401
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$124.5M	2020-12-31	2022-03-01	10-K	0000950170-22-002401
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$164,000	2019-12-31	2022-03-01	10-K	0000950170-22-002401
6	total debt	us-gaap:LongTermDebt	\$49.7M	2019-12-31	2021-02-25	10-K	0001564590-21-008382
7	book equity	us-gaap:StockholdersEquity	\$608.3M	2019-12-31	2023-03-01	10-K	0000950170-23-005336
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$644.6M	2019-12-31	2021-02-25	10-K	0001564590-21-008382
9	total debt	us-gaap:LongTermDebt	\$79.7M	2018-12-31	2020-02-25	10-K	0001564590-20-006390
10	book equity	us-gaap:StockholdersEquity	\$152.3M	2018-12-31	2022-03-01	10-K	0000950170-22-002401
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$249.2M	2018-12-31	2020-02-25	10-K	0001564590-20-006390
12	net income	us-gaap:NetIncomeLoss	-\$38.8M	2025-12-31	2026-03-02	10-K	0001193125-26-085818
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$6.7M	2025-12-31	2026-03-02	10-K	0001193125-26-085818
14	assets	us-gaap:Assets	\$685.3M	2024-12-31	2026-03-02	10-K	0001193125-26-085818
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$213.6M	2025-12-31	2026-03-02	10-K	0001193125-26-085818
16	gross profit	us-gaap:GrossProfit	\$81.4M	2024-12-31	2026-03-02	10-K	0001193125-26-085818
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$228.6M	2024-12-31	2026-03-02	10-K	0001193125-26-085818
18	gross profit	us-gaap:GrossProfit	\$165.5M	2023-12-31	2026-03-02	10-K	0001193125-26-085818
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$306.9M	2023-12-31	2026-03-02	10-K	0001193125-26-085818
20	gross profit	us-gaap:GrossProfit	\$242.5M	2022-12-31	2025-03-12	10-K	0000950170-25-037620
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$369.2M	2022-12-31	2025-03-12	10-K	0000950170-25-037620
22	gross profit	us-gaap:GrossProfit	\$461.9M	2021-12-31	2024-02-29	10-K	0000950170-24-022636
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$583.2M	2021-12-31	2024-02-29	10-K	0000950170-24-022636
24	current assets	us-gaap:AssetsCurrent	\$649.9M	2025-12-31	2026-03-02	10-K	0001193125-26-085818
25	current liabilities	us-gaap:LiabilitiesCurrent	\$194.5M	2025-12-31	2026-03-02	10-K	0001193125-26-085818
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.7B	2025-12-31	2026-03-02	10-K	0001193125-26-085818
27	operating income	us-gaap:OperatingIncomeLoss	-\$50.2M	2025-12-31	2026-03-02	10-K	0001193125-26-085818
28	book equity	us-gaap:StockholdersEquity	\$459.3M	2025-12-31	2026-03-02	10-K	0001193125-26-085818
29	liabilities	us-gaap:Liabilities	\$211.5M	2025-12-31	2026-03-02	10-K	0001193125-26-085818
30	depreciation amortization	us-gaap:Depreciation	\$200,000	2019-12-31	2022-03-01	10-K	0000950170-22-002401
31	interest expense	us-gaap:InterestExpense	\$7,000	2025-12-31	2026-03-02	10-K	0001193125-26-085818
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$21.7M	2020-12-31	2023-03-01	10-K	0000950170-23-005336
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$252,000	2020-12-31	2021-02-25	10-K	0001564590-21-008382
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$9.4M	2019-12-31	2022-03-01	10-K	0000950170-22-002401
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.5M	2019-12-31	2021-02-25	10-K	0001564590-21-008382
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$94.7M	2018-12-31	2021-02-25	10-K	0001564590-21-008382
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$58,000	2018-12-31	2021-02-25	10-K	0001564590-21-008382
38	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperati	\$32.8M	2017-12-31	2018-02-27	10-K	0001564590-18-003389
39	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$12,000	2017-12-31	2020-02-25	10-K	0001564590-20-006390
40	depreciation amortization	us-gaap:Depreciation	\$600,000	2020-12-31	2023-03-01	10-K	0000950170-23-005336
41	operating income	us-gaap:OperatingIncomeLoss	-\$19.7M	2020-12-31	2023-03-01	10-K	0000950170-23-005336
42	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$173.3M	2020-12-31	2023-03-01	10-K	0000950170-23-005336
43	income tax	us-gaap:IncomeTaxExpenseBenefit	\$745,000	2020-12-31	2023-03-01	10-K	0000950170-23-005336
44	current assets	us-gaap:AssetsCurrent	\$879.2M	2020-12-31	2022-03-01	10-K	0000950170-22-002401
45	current liabilities	us-gaap:LiabilitiesCurrent	\$307.4M	2020-12-31	2022-03-01	10-K	0000950170-22-002401
46	current assets	us-gaap:AssetsCurrent	\$855.0M	2019-12-31	2021-02-25	10-K	0001564590-21-008382
47	current liabilities	us-gaap:LiabilitiesCurrent	\$242.2M	2019-12-31	2021-02-25	10-K	0001564590-21-008382
48	assets	us-gaap:Assets	\$831.7M	2023-12-31	2025-03-12	10-K	0000950170-25-037620
49	assets	us-gaap:Assets	\$886.2M	2022-12-31	2024-02-29	10-K	0000950170-24-022636
50	shares outstanding	dei:EntityCommonStockSharesOutstanding	380,694	2013-02-20	2013-02-28	10-K	0001193125-13-084191
51	shares outstanding	dei:EntityCommonStockSharesOutstanding	136,059,695	2012-02-23	2012-02-29	10-K	0001193125-12-089181